

P24. COST-BENEFIT STUDY OF THE TREATMENT OF THE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.

Cristina Sorica, Ovidiu Potre, Ema Budai, Raluca Sima, Bogdan Trinca, Monica Pescaru, Mirela Nedelcu, Laura Toma

University of Medicine and Pharmacy "Victor Babeș", Timișoara, Department of Hematology, Timișoara, Romania

Introduction. Multiple myeloma is a malignancy of the plasma cells that produce monoclonal immunoglobulins that invade and destroy adjacent bone tissue. The treatment involves combined chemotherapy depending on the stage of the disease.

The aim of the study is to evaluate the cost-benefits of the treatment of the patients with newly diagnosed multiple myeloma from the Department of Hematology, Timisoara

Methods. We carried out a retrospective analytical case study for 105 patients with multiple myeloma from January 2008 until June 2013. Multiple myeloma was diagnosed by the presence of monoclonal immunoglobulin in the blood and excretion of light chains in urine (Kappa or Lambda), as plasma cells in the bone marrow more than 10%, and lytic bone lesions. The clinical examination, complete blood count, biochemical tests, x-ray (skeleton) were performed on all patients. CT was performed according to the clinician's recommendation.

Results. The average age of the patients was 60 years including 64% men and 36% women. Out of the 105 patients, 95 % presented bone pain, bone injuries and fractures, 35% patients had kidney failure, anemia, nausea, constipation, neurological symptoms. A total of 40 patients (38,09%) were treated with Alkeran and Dexamethasone; 30 patients (28,57%) VAD polychemotherapy followed by Velcade with Dexamethasone; 20 patients (19,04%) Alkeran with Dexamethasone followed by Velcade and 15 patients (14,28%) Velcade with Dexamethasone. The costs of treatment for a patient with Alkeran and Dexamethasone is about 1150 Euros (8 treatments), VAD 1820 Euros (8 treatments) and Velcade 27280 Euro (6 treatments). In our study 65% of patients currently present a complete remission.

Conclusion. This study demonstrates that the treatment with Velcade is the most expensive, it is the most effective and has the fewest side effects.